Leukemia, Myelocytic, Acute | Blasts Myeloid Percentage Peripheral blood | Blasts Bone marrow Percentage | MYELODYSPLASTIC SYNDROME | Acute Promyelocytic Leukemia Unresponsive to Treatment | Tretinoin | arsenic trioxide
Item
patients must have a diagnosis of aml (> 20% myeloid blasts in the peripheral blood or bone marrow) or mds with > 10% myeloid blasts in the bone marrow. patients with acute promyelocytic leukemia (apl) must be refractory to all-trans retinoic acid (atra) and arsenic trioxide.
boolean
C0023467 (UMLS CUI [1])
C0368761 (UMLS CUI [2,1])
C0439677 (UMLS CUI [2,2])
C0439165 (UMLS CUI [2,3])
C0229664 (UMLS CUI [2,4])
C1982687 (UMLS CUI [3,1])
C0439165 (UMLS CUI [3,2])
C3463824 (UMLS CUI [4])
C0023487 (UMLS CUI [5,1])
C0205269 (UMLS CUI [5,2])
C0040845 (UMLS CUI [6])
C0052416 (UMLS CUI [7])
Criteria Fulfill
Item
the patients must have one of the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Age | Recurrent disease | Refractory Disease | Prior Therapy Quantity | Patient Inappropriate Cytotoxic therapy | Patient Inappropriate Conventional Treatment | Poor performance status | Comorbidity
Item
age of 18 to 69 years; relapsed or refractory disease following at least one prior therapeutic regimen; not a candidate for cytotoxic or other conventional therapies due to disease refractoriness, poor performance status, or co-morbidities
boolean
C0001779 (UMLS CUI [1])
C0277556 (UMLS CUI [2])
C1514815 (UMLS CUI [3])
C1514463 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0030705 (UMLS CUI [5,1])
C1548788 (UMLS CUI [5,2])
C0677881 (UMLS CUI [5,3])
C0030705 (UMLS CUI [6,1])
C1548788 (UMLS CUI [6,2])
C2945704 (UMLS CUI [6,3])
C1831741 (UMLS CUI [7])
C0009488 (UMLS CUI [8])
Age | Prior Therapy Absent | Exception Hematopoietic Cell Growth Factors | Exception Hydroxyurea | Patient Inappropriate Cytotoxic therapy | Patient Inappropriate Conventional Treatment | Poor performance status | Comorbidity | Preference Personal
Item
age of 70 years or older; received no previous therapies (other than hematopoietic growth factors or hydroxyurea); not a candidate for cytotoxic or other conventional therapies due to poor performance status, co-morbidities, or personal preference
boolean
C0001779 (UMLS CUI [1])
C1514463 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0079490 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0020402 (UMLS CUI [4,2])
C0030705 (UMLS CUI [5,1])
C1548788 (UMLS CUI [5,2])
C0677881 (UMLS CUI [5,3])
C0030705 (UMLS CUI [6,1])
C1548788 (UMLS CUI [6,2])
C2945704 (UMLS CUI [6,3])
C1831741 (UMLS CUI [7])
C0009488 (UMLS CUI [8])
C0558295 (UMLS CUI [9,1])
C1519021 (UMLS CUI [9,2])
Age | Recurrent disease | Refractory Disease
Item
age of 70 years or older with relapsed or refractory disease
boolean
C0001779 (UMLS CUI [1])
C0277556 (UMLS CUI [2])
C1514815 (UMLS CUI [3])
Prior Therapy Discontinued Acute leukemia | Effects of Therapeutic procedure Patient recovered
Item
the patient must have discontinued all previous therapies for acute leukemia for at least 14 days and recovered from the acute effects of the therapy.
boolean
C1514463 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0085669 (UMLS CUI [1,3])
C1704420 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C1115804 (UMLS CUI [2,3])
ECOG performance status | Zubrod Performance Status
Item
patients must have an ecog (zubrod) performance status of 0-2
boolean
C1520224 (UMLS CUI [1])
C3714786 (UMLS CUI [2])
Able to take medication Oral | Patient Tolerable Oral medication
Item
patients must be able to take and tolerate oral medications
boolean
C4075001 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0030705 (UMLS CUI [2,1])
C4053931 (UMLS CUI [2,2])
C0175795 (UMLS CUI [2,3])
Organ function
Item
patients must have adequate organ function as specified in the protocol.
boolean
C0678852 (UMLS CUI [1])
Anticoagulation Therapy Absent | International Normalized Ratio | PTT Normal
Item
patients not on anti-coagulation must have an inr < 1.5 and a ptt within normal limits.
boolean
C0003281 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0525032 (UMLS CUI [2])
C0030605 (UMLS CUI [3,1])
C0205307 (UMLS CUI [3,2])
Pregnancy | Breast Feeding
Item
pregnant women or nursing mothers are not eligible for this trial.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Biological treatment | Cytotoxic Chemotherapy | Therapeutic radiology procedure
Item
patients may receive no other concurrent biologic therapy, cytotoxic chemotherapy or radiation therapy during this trial.
boolean
C1531518 (UMLS CUI [1])
C0677881 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
Medical condition Pre-existing Serious Quantity | Study Subject Participation Status Excluded
Item
patients with one or more serious preexisting medical conditions that, in the opinion of the investigator, would preclude participation in this study. see protocol for listing.
boolean
C3843040 (UMLS CUI [1,1])
C2347662 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,4])
C2348568 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
Central nervous system leukaemia Spinal Fluid Cytology | Central nervous system leukaemia Flow Cytometry | Central nervous system leukaemia Imaging
Item
patients with known central nervous system (cns) leukemia by spinal fluid cytology, flow cytometry or imaging
boolean
C1332884 (UMLS CUI [1,1])
C0007806 (UMLS CUI [1,2])
C1305671 (UMLS CUI [1,3])
C1332884 (UMLS CUI [2,1])
C0016263 (UMLS CUI [2,2])
C1332884 (UMLS CUI [3,1])
C0011923 (UMLS CUI [3,2])
Transplantation of autologous hematopoietic stem cell | Allogeneic Hematopoietic Stem Cell Transplantation | Side effects Interfere with Interpretation Toxicity
Item
patients with previous autologous or allogeneic stem cell transplantation who have current side effects and/or complications that in the opinion of the investigator can interfere with the interpretation of the toxicities.
boolean
C1831743 (UMLS CUI [1])
C1705576 (UMLS CUI [2])
C0001688 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0459471 (UMLS CUI [3,3])
C0600688 (UMLS CUI [3,4])